Skip to main navigation
BioCryst Pharmaceuticals, Inc. Logo
  • Home
  • News & Events
    Press Releases Events & Presentations
  • Stock
    Stock Quote & Chart Historic Stock Lookup Analyst Coverage
  • Corporate Governance
    Board of Directors Committee Composition Code of Conduct & Compliance Committee Charters Corporate Responsibility
  • Finance & Filings
    Financial Profile SEC Documents Proxy Online Quarterly Results
  • Investor Resources
    Investor FAQ Email Alerts RSS News Feeds

Press Releases

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 05, 2023
Read More
BioCryst to Present at Upcoming Investor Conferences
Aug 23, 2023
Read More
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 04, 2023
Read More
BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update
Aug 03, 2023
Read More
BioCryst to Report Second Quarter 2023 Financial Results on August 3
Jul 20, 2023
Read More
BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey
Jul 19, 2023
Read More
BioCryst to Participate in the 2023 US HAEA National Summit
Jul 17, 2023
Read More
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 06, 2023
Read More
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 06, 2023
Read More
BioCryst to Present at Upcoming Investor Conference
Jun 01, 2023
Read More
Pagination
  • Current page 1
  • Page 2
  • Page 3
  • …
  • Next page ›
  • Last page »

Contact Investor Relations

investorrelations@biocryst.com
+1 919.859.7910

Investor Tools

  • Print Page
  • Printed Materials
  • Email Alerts
  • RSS News Feeds
  • Share Page
  • © BioCryst Pharmaceuticals, Inc. All Rights Reserved. 2023
  • Facebook
  • Twitter
  • LinkedIn
  • RSS